Alan D. Michelson, MD
Dr. Michelson is Professor of Pediatrics and Professor of Medicine at Harvard Medical School in Boston, Massachusetts, U.S.A. He is also the Director of the Center for Platelet Research Studies and Director of the Thrombosis and Anticoagulation Program at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. He is a graduate of the University of Adelaide Medical School in Australia and is a former Fulbright Scholar.
Dr. Michelson is the editor of the textbook Platelets (Elsevier/Academic Press), which integrates the entire field of platelet biology, pathophysiology and clinical medicine into a comprehensive source of knowledge about platelets for clinicians, pathologists, and scientists. The first edition of Platelets, published in 2002, was the winner of the Best Book in Medical Science award from the Association of American Publishers and was called “landmark” by the New England Journal of Medicine. The 64-chapter, 1353-page third edition of Platelets, published in 2013, was the winner of the Highly Commended Prize in the category of Internal Medicine, British Medical Association (BMA) Medical Book Awards. The fourth edition of Platelets is in preparation.
Dr. Michelson has been an invited participant in numerous National Institutes of Health working groups, international workshops and consensus conferences (including Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines). Dr. Michelson is the co-organizer and co-chair of the biennial International Platelets Symposium. He is a past Chairman of the Platelet Physiology Scientific Subcommittee of the International Society on Thrombosis and Haemostasis.
Dr. Michelson has published more than 450 original research articles, original research abstracts, and invited reviews – nearly all on the topic of platelets. He has been the principal investigator on more than 100 research grants. Dr. Michelson has been an invited speaker at over 200 major medical conferences worldwide.
Wm. Andrew Heaton, MD
Andrew Heaton provides consulting services to Biotechnology and Diagnostics Companies in the Bay Area. Previously CMO of Novartis Diagnostics (Chiron Blood Testing) where he oversaw priority BLA approvals of two blood screening diagnostics assays, and associated testing platforms in association with Horlogic (Gen-Probe), for which he was the alliance manager. Most recently as corporate head of Transfusion Services at Northwell Health System he was responsible for a ~ 30 % reduction in blood cost/case while improving service quality and supporting two ACS Level 1 trauma service applications. Initiatives included a comprehensive cost management program, and development of value managed relationships with principal suppliers.
Areas of interest included therapeutic apheresis, ante-natal screening programs, specialized red cell testing and faculty practice revenues which achieved > 20% CAGR. In addition to providing consulting service for hospital and blood bank regulatory turnarounds to reopen a transfusion service subject to regulatory administrative action, he has also provided transfusion medicine litigation support. New product clinical studies were executed in the area of Bacterial Assay development and Platelet Additive Solutions. Prior to NSLIJ he had served as Director of Cell Therapy and Transplantation at the National Cord Blood Program.